Advertisement Dilon signs national agreement with MedAssets - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Dilon signs national agreement with MedAssets

Dilon Technologies, a provider of gamma imaging system optimized for early breast cancer detection, has signed a three-year agreement with a group purchasing organization MedAssets Supply Chain Systems, a MedAssets company.

The agreement, with an effective date of June 1, 2008 provides MedAssets’s customers access to Dilon’s cornerstone product, The Dilon 6800 gamma camera.

The Dilon 6800 performs a molecular breast imaging technique called breast-specific gamma imaging, which can detect lesions independent of tissue density and discover very early stage cancers, according to Dilon.